Your browser doesn't support javascript.
loading
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren, Zhenggang; Xu, Jianming; Bai, Yuxian; Xu, Aibing; Cang, Shundong; Du, Chengyou; Li, Qiu; Lu, Yinying; Chen, Yajin; Guo, Yabing; Chen, Zhendong; Liu, Baorui; Jia, Weidong; Wu, Jian; Wang, Junye; Shao, Guoliang; Zhang, Bixiang; Shan, Yunfeng; Meng, Zhiqiang; Wu, Jianbing; Gu, Shanzhi; Yang, Wei; Liu, Chao; Shi, Xuetao; Gao, Zhenyuan; Yin, Tao; Cui, Jiuwei; Huang, Ming; Xing, Baocai; Mao, Yilei; Teng, Gaojun; Qin, Yanru; Wang, Jinhai; Xia, Feng; Yin, Guowen; Yang, Yong; Chen, Mingxia; Wang, Yan; Zhou, Hui; Fan, Jia.
Afiliação
  • Ren Z; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.
  • Xu J; Digestive Oncology Department, The Fifth Medical Centre of PLA General Hospital, Beijing, China.
  • Bai Y; Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
  • Xu A; Department of Oncological Internal Medicine, Nantong Tumour Hospital, Nantong, China.
  • Cang S; Department of Internal Medicine-Oncology, Henan Provincial People's Hospital, Zhengzhou, China.
  • Du C; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Li Q; Abdominal Tumour Department, West China Hospital, Sichuan University, Chengdu, China.
  • Lu Y; Treatment and Research Centre for Liver Cancer Department 2, The Fifth Medical Centre of PLA General Hospital, Beijing, China.
  • Chen Y; Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Guo Y; Department of Tumours of Liver, Nan Fang Hospital, Guangzhou, China.
  • Chen Z; Oncology Department, The Second Hospital of Anhui Medical University, Hefei, China.
  • Liu B; Department of Oncology, Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
  • Jia W; General Surgery Department, Anhui Provincial Hospital, Hefei, China.
  • Wu J; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Wang J; Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, China.
  • Shao G; Department of Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou, China.
  • Zhang B; Department of Hepatobiliary Surgery, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
  • Shan Y; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Meng Z; Department of Traditional Chinese Medicine/Integrative Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.
  • Wu J; Oncology Department, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Gu S; Radioactive Interventional Department, Hunan Cancer Hospital, Changsha, China.
  • Yang W; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.
  • Liu C; Department of Pancreaticobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Shi X; Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, China.
  • Gao Z; Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Yin T; Department of Hepatobiliary Surgery, Hubei Cancer Hospital, Wuhan, China.
  • Cui J; Oncology Department, Bethune First Hospital of Jilin University, Changchun, China.
  • Huang M; Department of Minimally Invasive Interventional Medicine, Yunnan Cancer Hospital, Kunming, China.
  • Xing B; Hepatobiliary Pancreatic Surgery 1, Beijing Cancer Hospital, Beijing, China.
  • Mao Y; Live Surgery Ward, Peking Union Medical College Hospital, Beijing, China.
  • Teng G; Radiology Department, Zhongda Hospital Southeast University, Nanjing, China.
  • Qin Y; Department of Internal Medicine Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Wang J; Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.
  • Xia F; Department of Hepatobiliary Surgery, The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing, China.
  • Yin G; Intervention Department, Jiangsu Cancer Hospital, Nanjing, China.
  • Yang Y; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China.
  • Chen M; Department of Biostatistics and Information, Innovent Biologics, Suzhou, China.
  • Wang Y; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China.
  • Zhou H; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China.
  • Fan J; Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. Electronic address: fan.jia@zs-hospital.sh.cn.
Lancet Oncol ; 22(7): 977-990, 2021 07.
Article em En | MEDLINE | ID: mdl-34143971
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Métodos Terapêuticos e Terapias MTCI: Terapias_biologicas / Aromoterapia Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Anticorpos Monoclonais Humanizados / Medicamentos Biossimilares / Bevacizumab / Sorafenibe / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Prognostic_studies País/Região como assunto: Asia Idioma: En Revista: Lancet Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Métodos Terapêuticos e Terapias MTCI: Terapias_biologicas / Aromoterapia Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Anticorpos Monoclonais Humanizados / Medicamentos Biossimilares / Bevacizumab / Sorafenibe / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Prognostic_studies País/Região como assunto: Asia Idioma: En Revista: Lancet Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China